Group 1 - The company announced a share repurchase plan with a total expected amount between 30 million and 60 million RMB [1] - The repurchase will be conducted through centralized bidding and is intended for employee stock ownership plans or equity incentives [1] - The repurchase period is set from August 22, 2025, to August 21, 2026, with a maximum repurchase price of 25 RMB per share [1] Group 2 - As of August 28, 2025, the company has opened a dedicated account for the share repurchase and is in the process of setting up corresponding financial accounts [2] - The company will make repurchase decisions based on market conditions and will fulfill information disclosure obligations in a timely manner [2]

证券代码：600055 证券简称：万东医疗 公告编号：2025-043 北京万东医疗科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 | 重要内容提示： | | --- | 北京万东医疗科技股份有限公司董事会 | 回购方案首次披露日 | 2025/8/23 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 22 8 | 8 | 日~2026 | 年 | 21 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 0万股 | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | 累计已回购金额 | 0 ...

Group 1 - The core point of the article is that Wandong Medical (600055.SH) has not conducted any share buybacks as of August 29, 2025 [1]

Core Viewpoint - WanDong Medical (600055) is planning to repurchase shares with a budget of 30 million to 60 million yuan, aiming to enhance employee stock ownership and equity incentives [3][4]. Group 1: Stock Performance - As of August 29, 2025, WanDong Medical's stock closed at 17.73 yuan, down 1.77% from the previous week [1]. - The stock reached a weekly high of 18.5 yuan on August 26 and a low of 17.25 yuan on August 28 [1]. - The company's current total market capitalization is 12.465 billion yuan, ranking 28th out of 126 in the medical device sector and 1535th out of 5152 in the A-share market [1]. Group 2: Shareholder Information - As of August 22, 2025, the top ten shareholders and the top ten unrestricted shareholders hold the same shares, with Midea Group being the largest shareholder, owning 319,579,981 shares, which is 45.46% of the total share capital [2][4]. - Other notable shareholders include Jiangsu Yuyue Technology Development Co., Ltd., Huabao Zhongzheng Medical ETF, and Lin Jinkun [2]. Group 3: Share Repurchase Plan - The share repurchase will be conducted through centralized bidding, with a maximum price of 25 yuan per share and a planned repurchase period of 12 months from the board's approval date [3][4]. - The expected number of shares to be repurchased is between 1.2 million and 2.4 million, representing 0.17% to 0.34% of the total share capital [3][4]. - The company has established a dedicated securities account for the repurchase and has authorized management to handle the specifics of the repurchase [3].

Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. announced the share repurchase plan and provided details on the top ten shareholders and top ten unrestricted shareholders as of August 22, 2025 [1]. Summary by Category Share Repurchase Plan - The company has proposed a share repurchase plan, which was disclosed on August 23, 2025, on the Shanghai Stock Exchange [1]. Shareholder Information - The announcement includes the names, shareholdings, and proportions of the top ten shareholders and top ten unrestricted shareholders as of August 22, 2025. - The top shareholders include: 1. China Bank Co., Ltd. - Hua Bao CSI Medical Index Open-End ETF 2. China Merchants Bank Co., Ltd. - Southern CSI 1000 Open-End ETF - All shares listed are unrestricted circulating shares, and the top ten shareholders and top ten unrestricted shareholders have the same shareholding situation [1].

证券代码：600055 证券简称：万东医疗 公告编号：2025-041 北京万东医疗科技股份有限公司关于 以集中竞价交易方式回购股份的回购报告书 ? 回购股份方式：集中竞价交易方式。 ? 回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 ? 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来 3 个月、未来 6 个月不存在减持计划。 若上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规 定及时履行信息披露义务。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 回购股份金额：人民币3,000万元（含）-6,000万元（含）。 ? 回购股份资金来源：公司自有资金。 ? 回购股份用途：用于员工持股计划或股权激励。 ? 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 ? 相关风险提示： 导致本次回购方案无法顺利实施的风险； 及时到位，导致回购方案无法按计划实施的风险； 能存在回购 ...

回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 北京万东医疗科技股份有限公司关于 以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 回购股份金额：人民币3,000万元（含）-6,000万元（含）。 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 回购股份方式：集中竞价交易方式。 证券代码：600055 证券简称：万东医疗 公告编号：2025-041 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来 3 个月、未来 6 个月不存在减持计划。 若上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规 定及时履行信息披露义务。 相关风险提示： 1、本次回购可能存在回购期限内公司股票价格持续超出回购价格上限， 导致本次回购方案无法顺利实施的风险； 2、本次回购股份的资金来源于自有资金，存在回购股份所需资金未能 及时到位，导致回购方案无法按计划实施 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-042 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：自有资金 0.8 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用自有资金 0.1 亿元， 子公司使用自 有资金 0.7 亿元。 （三）资金来源 ...

特此公告。 北京万东医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第十届董事会第十次会议，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》。具体内容详见公司于 2025 年 8 月 23 日在上 海证券交易所网站披露的《万东医疗关于以集中竞价交易方式回购股份方 案的公告》（公告编号：2025-038）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指 引第7号—回购股份》等相关规定，现将董事会公告回购股份决议的前一个 交易日（即2025年8月22日）登记在册的前十大股东和前十大无限售条件股 东的名称、持股数量及比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 | | --- | --- | --- | --- | | | | | （%） | | 1 | 美的集团股份有限公司 | 319,579,981 | 45.46 | | 2 | 江苏鱼跃科技发展有限公司 | 18,031,825 | 2.56 | | 3 | 中国银行股份有限公司－华宝中证医疗 交易型开放式指数证券投资基金 | 12,687,111 | 1.80 ...

Core Insights - The company reported a revenue of 843 million yuan, representing a year-on-year increase of 20.46% [1] - The net profit attributable to shareholders was 51.3 million yuan, showing a year-on-year decline of 39.46% [1] - Research and development investment increased by 59.16%, with an R&D intensity of 15% [1] Business Strategy - The company is leveraging the "Healthy China 2030" strategy, focusing on breakthroughs in high-end medical imaging equipment technology and global market expansion [1] - In response to global supply chain adjustments and structural upgrades in the industry, the company is enhancing its R&D system, deepening market layout, and optimizing industrial collaboration [1] Technological Advancements - The company has made significant technological progress, with one-third of its workforce dedicated to R&D, focusing on high-end CT and self-developed core components [1] - The world's first helium-free MR has achieved mass production, eliminating the "bottleneck" risk associated with helium supply [1] - The quantum DSA, utilizing a self-controlled rare earth detector, is leading the way in low-dose angiography [1] - As of June 2025, the company has been granted 243 authorized intellectual property rights, which are widely applied in its main business [1]